CareNavigator

Australia's Medical Treatment Overseas Program: What Cancer Patients Need to Know About Funding Treatment in China

Important: The Medical Treatment Overseas Program is a competitive Australian government program with a low approval rate. Eligibility is not guaranteed, and families should confirm current requirements with the Department of Health and their treating specialist.

What Is the Medical Treatment Overseas Program (MTO)?

The Medical Treatment Overseas Program (MTO) is an Australian government initiative that provides financial support for eligible Australian patients to travel overseas for medical treatment that is not appropriately available in Australia for their specific case. Administered by the Department of Health and Aged Care under Section 6B of the Health Insurance Act 1973, the program is designed to help Australians with serious or complex conditions access treatments that either do not exist domestically or are not suitable for their individual clinical circumstances.

Importantly, the MTO is rarely approved and requires strong clinical justification. Pre-approval is mandatory before traveling. The program is not an entitlement or a routine funding pathway — it is a needs-based, case-by-case assessment. Even patients with serious diagnoses face a rigorous evaluation process, and approval is far from guaranteed.

The MTO covers actual treatment costs, travel, and accommodation for the patient, and in specific cases where a medical escort is clinically required, that may also be covered. However, the application process is demanding, documentation requirements are extensive, and the approval timeline can stretch from weeks to months. Australian patients considering this pathway should not view the MTO as a simple formality — it is a complex, competitive process that rewards thorough preparation and strong clinical evidence.

As of 2026, the MTO has historically funded treatment in the United States, United Kingdom, and New Zealand. China is less commonly associated with the program, but it is not excluded. Destinations are assessed on a case-by-case basis, and for treatments where China holds clear clinical advantages, a well-documented application can be competitive.

The Legal Framework — Health Insurance Act 1973 and Program Guidelines

The MTO operates under Section 6B of the Health Insurance Act 1973, which empowers the Australian Minister for Health to arrange services for Australians who require treatment overseas. This is the legal foundation of the program, and it makes clear that the MTO is a discretionary mechanism — not an automatic right.

Program guidelines are published on health.gov.au and are updated periodically. The framework is explicitly needs-based rather than entitlement-based. Each application is assessed on its individual clinical merits, meaning two patients with the same diagnosis may receive different outcomes depending on their specific clinical circumstances, the strength of their documentation, and the assessment committee's judgment.

This point is critical to understand: approval is not automatic, even for conditions where Australia has limited domestic options. The applicant must demonstrate that overseas treatment is the clinically optimal — not merely acceptable — choice for their specific case. The Health Insurance Act 1973 citation is good — but it reflects actual difficulty, not just legal framework.

The MTO Assessment Committee within the Department of Health and Aged Care reviews each application. The committee includes medical professionals who evaluate clinical justification across multiple dimensions: the evidence base for the proposed treatment, the patient's history in Australia, the suitability of the overseas facility, and overall cost-effectiveness relative to the clinical benefit. Decisions are not made lightly, and applicants should not assume success based on diagnosis alone.

Does the MTO Program Cover Cancer Treatment in China?

This is one of the most common questions Australian patients ask when exploring overseas cancer treatment — and it deserves a direct, honest answer.

China has not been a traditional MTO destination. The countries most frequently approved under the MTO have been the United States, United Kingdom, and New Zealand, largely because their healthcare systems have comparable standards to Australia's, making clinical equivalence easier to establish. Germany and Switzerland have also been approved in specific cases.

However — and this is important — the MTO program does not maintain a closed list of approved countries. The assessment committee evaluates each application based on clinical merit and the quality of documentation provided. This means a well-documented application for treatment in China is not automatically disqualified. It must demonstrate, persuasively and with supporting evidence, that the specific treatment being sought is not appropriately available in Australia for this particular patient.

For cancer treatments where China has clear clinical advantages — such as proton therapy for certain pediatric brain tumors, or CAR-T cell therapy for relapsed or refractory blood cancers — a strong clinical case can be made for China as a destination. China's growing international patient infrastructure, including JCI-accredited hospitals and dedicated English-language international patient departments, has made it a more viable MTO destination than it was even three years ago.

A critical legal distinction to understand: a treatment does not need to be approved or available in Australia for the MTO to fund it overseas. The program asks a specific question: is the treatment "not appropriately available in Australia" for this patient? This patient-specific test is central to every MTO decision.

What Makes a Treatment "Not Appropriately Available in Australia"

This is the core legal and clinical test for MTO eligibility. The question is not simply whether a treatment exists in Australia — it is whether the treatment is available in a form that is clinically appropriate for this specific patient.

For cancer patients, examples of cases that have successfully passed this test include proton therapy for pediatric brain tumors (where Australia has limited capacity and long waiting lists), CAR-T cell therapy for relapsed or refractory blood cancers where Australia's program is not accessible, and clinical trial participation where the trial is not available in Australia.

The patient's individual clinical circumstances matter significantly. A treatment that is broadly available in Australia may still be "not appropriately available" for a specific patient if they have exhausted all Australian options, experienced treatment failure, or have a clinical profile that makes standard Australian approaches unsuitable.

How Australian Children Are Already Accessing Proton Therapy Overseas

Australian children have already received government-funded proton therapy overseas — this is a factual, precedented pathway that should give families both hope and realistic context.

The Hospital Research Foundation (HRF) launched a dedicated proton therapy grants program in 2025 specifically for Australian children. This program provides funding to access proton therapy at overseas centers that treat pediatric patients, including centers in the USA, Japan, and increasingly in Asia. This initiative is separate from the MTO, but it carries significant weight: it demonstrates that Australian institutional bodies recognize the clinical need for better access to proton therapy for Australian children.

For MTO applications, the HRF precedent matters in a specific way. It establishes that Australian institutions — including government-adjacent bodies — recognize the clinical value of overseas proton therapy for children. This does not guarantee MTO approval for any individual child, but it does strengthen the argument that domestic capacity is insufficient to meet demand, and that overseas access is clinically justified.

For children with diagnoses such as medulloblastoma, craniopharyngioma, and other pediatric brain tumors where proton therapy is the standard of care, the clinical case for MTO funding is particularly strong. The evidence base for proton's benefits in pediatric patients — including cognitive preservation, reduced neuroendocrine side effects, and significantly lower risk of secondary malignancies compared to conventional photon radiation — is robust and published in peer-reviewed literature. MTO assessors have a clinical evidence wall to contend with.

For adult cancer patients, the MTO calculus is more complex. The clinical evidence for proton's advantage over photon therapy is well-established for certain adult cancers — head and neck cancers, nasopharyngeal carcinoma (NPC), prostate cancer, and sarcomas near critical organs — but it is more nuanced than for pediatric cases. Adult applicants should not assume approval based on diagnosis alone; the clinical case must be specific, documented, and persuasive.

Adults who have exhausted all Australian options for advanced or rare cancers — including access to clinical trials not available domestically — may also have viable MTO cases, particularly for treatments such as CAR-T and novel immunotherapy approaches where Australia's access remains limited.

The MTO Application Process — Step by Step

Step 1: Specialist Doctor Referral and Clinical Justification

The MTO application must be initiated by an Australian specialist doctor — not by the patient or their family directly. This is a non-negotiable requirement.

The referring specialist must provide a detailed clinical justification that: explains why the specific patient needs treatment overseas rather than in Australia; identifies precisely why the treatment is not appropriately available in Australia for this patient specifically (not just generally); details all treatment already attempted in Australia and why those options have been exhausted or are clinically unsuitable; and provides supporting clinical evidence to substantiate the case.

This clinical justification is the single most important document in the entire application. Its quality determines the application's competitiveness.

Step 2: Identifying a Suitable Overseas Treatment Facility

The application must identify a specific overseas hospital and treating physician — not merely a country of destination. The hospital must be able to demonstrate standards of care comparable to Australian hospitals. JCI (Joint Commission International) accreditation is highly useful evidence of this.

For Chinese hospitals, several institutions have international patient departments experienced in supporting overseas funding applications. These hospitals can provide the documentation — acceptance letters, physician credentials, treatment protocols, cost estimates — that the MTO Assessment Committee requires.

Step 3: Submitting the MTO Application to the Department of Health

Applications are submitted to the Department of Health and Aged Care's MTO Assessment Committee at [MTO@health.gov.au](mailto:MTO@health.gov.au). Required documents typically include the specialist referral letter and clinical justification, overseas hospital acceptance letter, detailed estimated cost of treatment, patient passport copies, supporting medical evidence, and documentation of the overseas facility's credentials.

Incomplete applications are returned or delayed — thoroughness is essential.

Step 4: What the MTO Assessment Committee Reviews

The committee reviews applications across several dimensions: strength and specificity of clinical justification; evidence that the treatment is not available in Australia for this patient specifically; suitability and credentialing of the overseas facility; overall cost-effectiveness relative to clinical benefit; and any independent medical advice the committee seeks. Processing time varies but typically ranges from 6 to 12 weeks from submission to decision.

Step 5: Approval, Funding, and Travel Arrangements

If approved, the MTO provides funding for: treatment costs (pre-approved amounts only — actual costs above the pre-approved cap become the patient's responsibility); flights for the patient; and accommodation for the patient and, if clinically required, accommodation for a companion.

The companion coverage requires specific clinical justification — it is not automatically approved. If the treating specialist certifies that a medical escort is clinically necessary for the patient's safety or treatment adherence, this can be included in the application. Approval for companion coverage is not guaranteed and must be separately justified. Funding is paid in installments tied to treatment milestones.

What Treatments Are Typically Approved vs. Not Approved Under MTO

Understanding the approval landscape helps set realistic expectations before investing time in an application.

Treatments commonly approved include: proton therapy for pediatric patients where Australia's domestic capacity is insufficient; CAR-T cell therapy for blood cancer patients where Australia's CAR-T program is not accessible; treatments for rare cancers available at high-volume international centers but with no equivalent in Australia; and clinical trial participation where the trial is not available in Australia and preliminary evidence supports potential benefit.

Treatments less likely to be approved include: treatments available in Australia in an equivalent form; treatments where the clinical advantage of going overseas is not clearly demonstrated with evidence; procedures considered purely experimental without a published evidence base; cosmetic or elective procedures; and situations where the application relies primarily on patient preference rather than clinical necessity.

The approval bar is high, and the process is competitive. A "may be eligible" designation in any resource does not imply likely approval. The majority of applications are not approved on first submission. Even for patients who appear to meet the clinical criteria, the quality of the application determines the outcome.

How Long Does MTO Approval Take? Timeline Expectations

Standard MTO applications take 6 to 12 weeks from the date of submission to decision. This assumes the application is complete, the documentation is thorough, and no additional information is required. Complex cases with incomplete documentation can take 4 to 6 months.

Patients should begin the MTO application process as early as possible — ideally before making any commitments to overseas treatment plans, deposits, or travel arrangements. Anticipate multiple rounds of correspondence with the Department of Health, and prepare for the possibility that the committee may request additional specialist opinions or documentation.

The approved funding amount is typically paid in installments tied to treatment milestones — not as a lump sum upfront. Patients need to plan for initial out-of-pocket expenses that will be reimbursed retroactively.

What Happens After You Return to Australia — Follow-Up Care and Reporting Requirements

MTO recipients are required to provide a post-treatment report from the overseas treating physician within a specified timeframe following treatment completion. The report must document treatment provided, clinical outcomes observed during treatment, any complications or adverse events, and projected follow-up care requirements.

This reporting requirement is part of the program's accountability framework. It also contributes to the evidence base that informs future MTO decisions — meaning each successful application and resulting report helps build the case for subsequent patients with similar clinical profiles.

Ongoing follow-up care in Australia must be coordinated with the patient's Australian specialist. The MTO does not fund long-term ongoing care in Australia — it funds the overseas treatment episode and associated travel. The transition back to Australian clinical care should be planned in advance and documented in the application's follow-up plan.

How CareNavigator Supports Australian Patients Through the MTO Process

CareNavigator works alongside Australian patients and their specialist teams to navigate the MTO pathway — providing logistical, informational, and documentary support without replacing the clinical role that must remain with the patient's Australian doctor.

Specifically, CareNavigator helps by: identifying appropriate Chinese hospitals with international patient departments experienced in supporting MTO applications; organizing medical records and assisting with documentation preparation for the specialist; clarifying Chinese hospital international patient processes so that once MTO approval is received, the path to treatment is clear; and coordinating in-country logistics including accommodation, interpretation, and hospital admission.

CareNavigator does not initiate or sign MTO applications. The clinical justification must be prepared and signed by the patient's Australian specialist — this is both a program requirement and a clinical necessity.

Frequently Asked Questions

Q1: What is Australia's Medical Treatment Overseas Program (MTO) and who is eligible?

A1: The Medical Treatment Overseas Program (MTO) is an Australian government program that funds eligible Australian citizens and permanent residents to travel overseas for medical treatment that is not appropriately available in Australia for their specific case. Administered by the Department of Health and Aged Care under the Health Insurance Act 1973, the program is needs-based — each application is assessed on its individual clinical merits. Importantly, the program is competitive with a low approval rate. Eligibility is not guaranteed, even for serious conditions. Pre-approval is mandatory before traveling.

Q2: Does the MTO program cover cancer treatment in China for Australian patients?

A2: The MTO program does not maintain an approved country list — it assesses each application on clinical merit. China has not been a traditional MTO destination, but it is not excluded. For cancer treatments where China has clear clinical advantages — such as proton therapy for certain pediatric brain tumors or CAR-T cell therapy for specific blood cancers — a well-documented application can make a strong case for China as a destination. Australia's Hospital Research Foundation has also funded Australian children to access proton therapy in overseas centers, including in Asia, setting an institutional precedent. However, approval is not guaranteed and requires persuasive clinical documentation.

Q3: How do I apply for MTO funding for my child's cancer treatment overseas?

A3: The MTO application must be initiated by an Australian specialist doctor — it cannot be initiated by the patient or family directly. The process is: (1) Ask your specialist if they will support an MTO application and prepare a detailed clinical justification; (2) With your specialist, identify a specific overseas treatment facility that can provide the documentation and credentials required; (3) Submit the complete application package to the Department of Health's MTO Assessment Committee; (4) Await the committee's decision — typically 6–12 weeks; (5) If approved, receive pre-approved funding and proceed with travel and treatment. CareNavigator can help identify appropriate Chinese hospitals, organize medical records, and clarify logistics — but the specialist must lead the clinical components of the application.

Q4: What treatments are typically approved under the MTO program?

A4: Treatments commonly approved include proton therapy for pediatric brain tumor patients (where Australia's domestic capacity is insufficient), CAR-T cell therapy for blood cancer patients where Australia's program is not accessible, treatments for rare cancers with no Australian equivalent, and clinical trial participation where the trial is unavailable in Australia. Treatments are less likely to be approved if an equivalent treatment is available in Australia, if the clinical advantage of going overseas is not clearly demonstrated, or if the treatment is considered experimental without a published evidence base. The approval bar is high — a majority of applications are not approved on first submission.

Q5: How long does it take to get MTO approval and how much funding is provided?

A5: MTO applications typically take 6–12 weeks from submission to decision, though complex cases can take 4–6 months. If approved, the MTO provides funding for treatment costs (up to a pre-approved amount), flights for the patient, and accommodation for the patient and a companion if clinically required (companion coverage must be specifically justified and is not automatically approved). Funding is capped at the pre-approved estimated cost of treatment — actual costs exceeding the approved cap become the patient's responsibility. We strongly recommend beginning the application process as early as possible, before committing to any overseas treatment plans, deposits, or travel arrangements.

Next Steps — Speak with CareNavigator

If you are an Australian patient or family exploring treatment options overseas, CareNavigator can help you understand whether the MTO program may be a realistic pathway for your situation.

Start with an Initial Strategy Call to review your clinical situation, treatment history, and the practical steps needed before any overseas pathway is pursued.
Book Your Initial Strategy Call — USD 29

References & Source Notes

Back to CareNavigator Insights